AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2022
May 11, 2022
30751_dirs_2022-05-11_b36590b9-4de2-439b-be9e-8bae9720a066.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-05-09
Reporting Person: Larkin Finbar (SVP, Technical Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-09 | Ordinary Shares | S | 1747 | $148.9369 | Disposed | 19462 | Direct |
Footnotes
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.92 to $149.91 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.